RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oryzon Genomics Stock

Oryzon Genomics EBIT 2024

Oryzon Genomics EBIT

-7.5 M EUR

Ticker

ORY.MC

ISIN

ES0167733015

WKN

A2ACV2

In 2024, Oryzon Genomics's EBIT was -7.5 M EUR, a 64.97% increase from the -4.55 M EUR EBIT recorded in the previous year.

The Oryzon Genomics EBIT history

YEAREBIT (undefined EUR)
2029e-
2028e395.91
2027e203.29
2026e-3.06
2025e-3.83
2024e-7.5
2023-4.55
2022-5.49
2021-7.01
2020-4.29
2019-3.83
2018-2.92
2017-4.32
2016-4.58
2015-0.21
201410.74
2013-1.02
20120.1

Oryzon Genomics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oryzon Genomics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oryzon Genomics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oryzon Genomics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oryzon Genomics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oryzon Genomics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oryzon Genomics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oryzon Genomics’s growth potential.

Oryzon Genomics Revenue, EBIT and net profit per share

DateOryzon Genomics RevenueOryzon Genomics EBITOryzon Genomics Net Income
2029e610.94 M undefined0 undefined288.55 M undefined
2028e220.19 M undefined395.91 M undefined97.18 M undefined
2027e119.34 M undefined203.29 M undefined52.19 M undefined
2026e6.31 M undefined-3.06 M undefined-2.66 M undefined
2025e6.37 M undefined-3.83 M undefined499,711.45 undefined
2024e1.73 M undefined-7.5 M undefined-3.32 M undefined
20230 undefined-4.55 M undefined-3.35 M undefined
20220 undefined-5.49 M undefined-4.23 M undefined
20210 undefined-7.01 M undefined-4.69 M undefined
20200 undefined-4.29 M undefined-3.4 M undefined
20190 undefined-3.83 M undefined-3.68 M undefined
20180 undefined-2.92 M undefined-1.18 M undefined
201720,000 undefined-4.32 M undefined-5.2 M undefined
2016740,000 undefined-4.58 M undefined-5.45 M undefined
20154.25 M undefined-210,000 undefined-990,000 undefined
201413.12 M undefined10.74 M undefined6.65 M undefined
201340,000 undefined-1.02 M undefined-1.8 M undefined
2012470,000 undefined100,000 undefined-610,000 undefined

Oryzon Genomics stock margins

The Oryzon Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oryzon Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oryzon Genomics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oryzon Genomics's sales revenue. A higher gross margin percentage indicates that the Oryzon Genomics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oryzon Genomics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oryzon Genomics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oryzon Genomics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oryzon Genomics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oryzon Genomics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oryzon Genomics Margin History

Oryzon Genomics Gross marginOryzon Genomics Profit marginOryzon Genomics EBIT marginOryzon Genomics Profit margin
2029e-4,700 %0 %47.23 %
2028e-4,700 %179.8 %44.13 %
2027e-4,700 %170.35 %43.74 %
2026e-4,700 %-48.54 %-42.25 %
2025e-4,700 %-60.12 %7.84 %
2024e-4,700 %-434.57 %-192.36 %
2023-4,700 %0 %0 %
2022-4,700 %0 %0 %
2021-4,700 %0 %0 %
2020-4,700 %0 %0 %
2019-4,700 %0 %0 %
2018-4,700 %0 %0 %
2017-4,700 %-21,600 %-26,000 %
2016-217.57 %-618.92 %-736.49 %
201550.35 %-4.94 %-23.29 %
201495.05 %81.86 %50.69 %
2013825 %-2,550 %-4,500 %
2012387.23 %21.28 %-129.79 %

Oryzon Genomics Aktienanalyse

What does Oryzon Genomics do?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Oryzon Genomics's EBIT

Oryzon Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oryzon Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oryzon Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oryzon Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oryzon Genomics stock

How much did Oryzon Genomics achieve in EBIT for the current year?

In the current year, Oryzon Genomics has achieved an EBIT of -7.5 M EUR.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Oryzon Genomics.

How has the EBIT of Oryzon Genomics developed in recent years?

The EBIT of Oryzon Genomics has increased by 64.974% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Oryzon Genomics?

The EBIT of Oryzon Genomics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Oryzon Genomics pay?

Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Oryzon Genomics?

The current dividend yield of Oryzon Genomics is .

When does Oryzon Genomics pay dividends?

Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oryzon Genomics?

Oryzon Genomics paid dividends every year for the past 0 years.

What is the dividend of Oryzon Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oryzon Genomics located?

Oryzon Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oryzon Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oryzon Genomics from 9/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Oryzon Genomics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Oryzon Genomics in the year 2023?

In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.

In which currency does Oryzon Genomics pay out the dividend?

The dividends of Oryzon Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oryzon Genomics

Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.